


Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2132.099APPLICATION NO.  
09/993,295INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
JACKOWSKI et al.FILING DATE  
11/23/01GROUP  
1741  
1641

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LVC	5,062,935	11/91	Schlag et al.			
LVC	6,020,208	02/00	Hutchens et al.			
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
LVC Y	WO 93/24834	12/93	PCT		X	
/ Y	WO 90/14148	11/90	PCT		X	
/ Y	WO 98/07036	02/98	PCT			X
LVC Y	WO 98/07036	02/98	PCT (translation)		X	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LVC	p	Takahashi et al., "Rapid and Sensitive Immunoassay for the Measurement of Serum S100B Using Isoform-specific Monoclonal Antibody", Clinical Chemistry 45, No. 8, (1999) pp. 1307-1311.
LVC	p	Richter et al., "Composition of the peptide fraction in human blood plasma: database of circulating human peptides", Journal of Chromatography B; 726 (1999) pp. 25-35.


EXAMINER

O'Connor Cook

DATE CONSIDERED

1/4/05

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
MAY 19 2003

Sheet 1 of 1

Form PTO-1449  
(Rev. 2-88)

TC 1700

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
2132.099

APPLICATION NO.  
09/993,295

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
JACKOWSKI et al.

FILING DATE  
11/23/01

GROUP  
1741 164

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LVC	6,329,500	12/01	Webb et al.			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
LVC	WO 02/059604 ✓	08/02	PCT			X
LVC	WO 98/07036 ✓	02/98	PCT			X

RECEIVED

MAY 22 2003

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LVC	✓	Van Cool, "α2-Macroglobulin Expression in Neuritic-Type Plaques in Patients With Alzheimer's Disease", Neurobiology of Aging (1993) Vol. 14, No. 3, pp. 233-237.
	✓	Ahmad, et al., "A Study of Plasma Alpha-2-Macroglobulin Levels in Type 2 Diabetic Subjects with Microalbuminuria", J. Assoc. Physicians of India (2001), Vol. 49, pp. 1062-1065.
	✓	Sesboue, et al., "Quantitative study of human blood alpha-1-antitrypsin, alpha-2-macroglobulin and inter-alpha-trypsin-inhibitor with respect to plasma renin activity", Clinica Chimica Acta (1983) Vol. 135, No. 1, pp. 23-34.
LVC	✓	DATABASE EMBL Online! Teich et al., "Alpha-2-macroglobulin (fragment)", retrieved from EMBL, Database accession no. Q9BQ22, XP-002237293.

EXAMINER

Olisa. X. Cook

DATE CONSIDERED

1/5/05

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/993,295
--------------------	------------

<b>Filing Date</b>	11/23/2001
--------------------	------------

First Named Inventor	George Jackowski
----------------------	------------------

Art Unit	1741
----------	------

Examiner Name	L. Clark
---------------	----------

Attorney Docket Number	2132.099
------------------------	----------

RECEIVED

**ACT 20 2003**

TC 1700

Sheet	1	of	2
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
WC		WO01/75454	10/11/2001	Oxford Glycosciences	_____	
				(UK) Ltd and Pfizer Inc	_____	
WC	b	WO01/63280	08/30/2001	Rhode Island Hospital	_____	
				a Lifespan Partner	_____	
					_____	
					_____	

**Examiner  
Signature**

Desa. & Cook


Date Considered

1/4/04 Wc

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	09/993,295
Filing Date	11/23/2001
First Named Inventor	George Jackowski
Art Unit	1741/641
Examiner Name	L. Cook
Attorney Docket Number	2132.099

RECEIVED

OCT 20 2003

TG 1700

Sheet 2 of 2

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
L/C	X	C. BRISTOW et al, "Specific Activity of alpha1 Proteinase Inhibitor and alpha2Macroglobulin in Human Serum: Application to Insulin-Dependent Diabetes Mellitus", Clin Immunol Immunopath, 89(3):247-259 (December, 1998)	
	X	G. TREFZ et al, "Establishment of an Enzyme-Linked Immuno-Sorbent Assay for Urinary Trypsin Inhibitor by Using a Monoclonal Antibody", Journal of Immunoassay, 12(3):347-369 (1991)	
	X	Y. MA et al, "Transgenic Mice Overexpressing gamma-aminobutyric Acid Transporter Subtype 1 Develop Obesity", Cell Research, 10(4):303-310 (December, 2000)	
	X	H. BLOEKER et al, "Hypothetical Protein", Database Accession No. Q9H030, XP002249055 (March, 2001) Abstract	
L/C	X	T. NAGASE et al, "Hypothetical Protein KIAA1697", Database Accession No. Q9C0G6, XP002249056 (June, 2001) Abstract	

Examiner Signature	<i>Rosa L Cook</i>	Date Considered	1/4/05 L/C
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.